Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Trial for Evaluation of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma

NCT03798314 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03798314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03798314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Trial for Evaluation of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
January 30, 2019
Completion date
September 15, 2021
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent nervous system lymphoma, recurrent primary vitreoretinal dlbcl, refractory nervous system lymphoma, refractory primary vitreoretinal dlbcl